It is estimated that over 350 million people around the world are infected with hepatitis B and 185 million with hepatitis C virus. Due to their prevalence both conditions are considered a global burden and require a multidisciplinary approach. Lack of clear and consistent guidelines for the treatment of rheumatoid arthritis with co‑existing viral hepatitis remains a significant therapeutic problem. Especially in regards to the risk of hepatitis reactivation and potential hepatotoxicity of drugs. This paper focuses on rheumatoid arthritis as one of the most common inflammatory joint disorders. It provides a review of studies and guidelines related to the arthritis treatment and a risk of adverse effects in patients with concomitant viral hepatitis.